fbpx
Thaena press release

[Press Release] InVivo Biosystems and Thaena Announce Novel Metabolite Research Platform With Compelling Longevity and Healthspan Implications and Outcomes

– InVivo Biosystems, experts in preclinical in vivo testing and CRISPR genome editing, and Thaena Inc., a science-based wellness company developing novel microbiome-based therapies, today announced measurably superior healthspan and lifespan results from research on ThaenaBiotic™ powder, a sterilized postbiotic mixture derived from healthy human stool.

EUGENE, ORE. AND PORTLAND, ORE. (PRWEB) AUGUST 31, 2022

InVivo Biosystems, experts in preclinical in vivo testing and CRISPR genome editing, and Thaena Inc., a science-based wellness company developing novel microbiome-based therapies, today announced measurably superior healthspan and lifespan results from research (1) on ThaenaBiotic™ powder, a sterilized postbiotic mixture derived from healthy human stool. The mix of compounds significantly improved both lifespan and healthspan in Caenorhabditis elegans, the latter outperforming both Resveratrol and Rapamycin control groups when tested on the InVivo Vitality Platform.

“We are investigating a novel approach to looking at the metabolites or postbiotics that the human microbiota produces. The mixture surprised us when it significantly extended lifespan and healthspan,” said Andrea McBeth, co-founder of Thaena.

“We are investigating a novel approach to looking at the metabolites or postbiotics that the human microbiota produces. The mixture surprised us when it significantly extended lifespan and healthspan,” said Andrea McBeth, co-founder of Thaena. “Over the past decade, fecal transplant use in clinical trials has challenged our understanding of the role the microbiome plays in immune, neurologic, and metabolic health. We’ve learned that not only does the composition of the microbiome matter from a species-viewpoint, but also what it produces. The InVivo Vitality Platform provided a new and more cost-effective way to investigate how such a complex mixture of small molecules produced by the microbiome could impact longevity and healthspan. We are incredibly excited by these findings and believe this will open a new world of discovery for longevity innovation.”

The study, undertaken by InVivo Biosystems on behalf of Thaena, utilizes C. elegans as the scientifically standard model organism that has contributed to the discovery of many compounds with potential life- and healthspan extending benefits. The short lifespan of these animals, paired with the ability to determine whether genetic pathways such as mTOR or insulin signaling are involved, make them a powerful tool for studying longevity effects. Treatment with ThaenaBiotic protected the animals from the effects of oxidizing chemicals better than Vitamin C and cause the animals to continue healthy movement patterns in late life. The two companies are now undertaking a transcriptomics study to determine the role of the underlying genetics in creating these health benefits, also known as the mechanism of action.

Kat McCormick, PhD., vice president of Product at InVivo Biosystems, added, “We, along with Thaena, didn’t expect to see these findings and are excited to move forward together to expand research into how and why this treatment affects longevity. We are excited that our scientific services enable growth and product development for new companies like Thaena that will fuel new options and innovation in the health and wellness space. It really is a cutting edge, novel scientific approach to looking at how gut health and longevity are interrelated and a cost-effective way for Thaena to deliver scientifically proven wellness products to the market.”

The age-tech and longevity industry is one of the fastest growing segments and has expanded into a massive marketplace serving an aging population of baby boomers. In 2021, the global anti-aging market was estimated to be worth $60.42 billion. It is expected to be worth around $119.6 billion by 2030 and growing at a compound annual growth rate (CAGR) of 7.9 percent from 2022 to 2030. (2)

The InVivo Efficacy Evaluation Platform

The InVivo Efficacy Evaluation Platform can quickly and economically test a compound or a formulation’s ability to impact the genes and hallmarks of good health with large sample sizes of live animals in less than four months. Scientific testing via the InVivo Vitality Platform helps the industry deliver confirmation of specific benefits as well as assist companies in developing these products. The platform uses automated scanning to produce smooth, high-resolution survival curves and to help ensure reproducibility, detection power, and robust conclusions.

The InVivo Efficacy Evaluation Platform offers the following studies:

  • Genetic Signature Study: determine how a compound or formulation affects gene expression using RNAseq and transcriptomics technology. Data Delivered as quickly as three months.
  • Vitality Study: perform lifetime monitoring of a large population of animals to determine whether compounds and formulations affect lifespan and healthspan. Data Delivered as quickly as four months.
  • Antioxidant Capacity Study: uncover whether a compound or formulation has antioxidant properties using a standardized reactive oxygen species exposure assay. Data Delivered as quickly as two months.
  • Mitochondrial Function Study: investigate the impact of a compound or formulation on mitochondrial function across the lifespan. Data Delivered as quickly as four months.

# # #

  1. Vitality & Antioxidant Study Report: or https://www.thaena.com/science
  2. Source: Precedence Research

InVivo Biosystems Founded in Eugene, InVivo Biosystems provides end-to-end services to help pharmaceutical, nutraceutical, biotechnology companies and academic research institutions around the globe accelerate their research and drug development efforts. The company’s mission is to build the world’s most effective genetic animal models to advance human health. An expert in zebrafish and C. elegans models, InVivo Biosystems creates custom genome-edited C. elegans and zebrafish models to enable aging and other disease studies. In addition, InVivo Biosystems provides in-vivo analytical services to produce data and insights for companies that need to quickly make go/no-go decisions in the early-stage development of new compounds. For more information, visit http://www.invivobiosystems.com or the company’s blog: InVivo Insights.

Thaena
A female-founded wellness company based in Portland, Ore. that is dedicated to balancing the microbial ecosystems by leveraging the potential of the human microbiome. The Thaena Team is working to develop evidence-based microbiome-related products and an educational platform supported by the most up-to-date research. The company is pioneering an innovative method for processing human stool that maintains a complex mixture of whole biome molecules (postbiotics) that represent the entirety of a healthy person’s gut ecosystem. Thaena’s first product, ThaenaBioticTM, is the first-of-its-kind whole biome-derived dietary supplement composed entirely of postbiotic molecules. For more information, visit http://www.thaena.com.

For More Information:
Wenlan Hu, VP of Marketing
InVivo Biosystems
541-206-8430
[email protected]
Andrea McBeth, Co-founder
XThaena Inc.
503-506-8732
[email protected]

About The Author

InVivo Biosystems

InVivo Biosystems provides essential services to help pharmaceutical, nutraceutical, biotechnology companies and academic research institutions around the globe accelerate their research and drug development efforts. An expert in CRISPR genome editing, InVivo Biosystems creates custom genome edited C. elegans and zebrafish models to enable aging and other disease studies. In addition, InVivo Biosystems provides in-vivo analytical services to produce data and insights for companies that need to make go/no-go decisions quickly in early-stage development of new compounds.

Share this articles

Facebook
Twitter
Pinterest
LinkedIn
InVivo Biosystems

About the Author:

Connect with us